---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041187"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:09:39.621030+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance

## Summary
- Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.
- The Panel will consider the company's plan to regain compliance with both the bid price and MVLS rules at a hearing.
- FibroBiologics filed a proxy seeking shareholder approval for a reverse stock split (1:5 to 1:30) to address bid price deficiency.
- Trading continues pending the Panel's decision; no assurance of an extension or successful compliance.

## SEC filing metadata
- accession: 0001193125-26-041187
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526041187/0001193125-26-041187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526041187/fblg-20260203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041187
- JSON: https://secwatch.observer/filing/0001193125-26-041187.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041187.txt

## Key facts
- Listing & Compliance Notices
  FibroBiologics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(a)(2), 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(a)(2), 5550(b)(2)
  source text: February 3, 2026, the Company received formal notice from the Staff that, based upon the Company’s continued non-compliance with the MVLS Rule, the deficiency serves as an additional basis for the delisting of the Company’s securities from Nasdaq (the “Notice”). The Notice indicated that, in addition to the previously-reported bid price deficiency under Listing Rule 5550(a)(2) (the “Bid Price Rule”), the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s plan to regain compliance with the MVLS Rule in their decision regarding the Company’s request for continued listing on The Nasd
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312526041187/0001193125-26-041187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.